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Abstract
West Nile virus (WNV) is a positive-stranded RNA virus belonging to the Flaviviridae family, a large family with 3
main genera (flavivirus, hepacivirus and pestivirus). Among these viruses, there are several globally relevant human
pathogens including the mosquito-borne dengue virus (DENV), yellow fever virus (YFV), Japanese encephalitis virus
(JEV) and West Nile virus (WNV), as well as tick-borne viruses such as tick-borne encephalitis virus (TBEV). Since the
mid-1990s, outbreaks of WN fever and encephalitis have occurred throughout the world and WNV is now endemic
in Africa, Asia, Australia, the Middle East, Europe and the Unites States. This review describes the molecular virology,
epidemiology, pathogenesis, and highlights recent progress regarding diagnosis and vaccination against WNV
infections.
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1. Introduction
West Nile virus (WNV) is a zoonotic mosquito-trans-
mitted arbovirus belonging to the genus Flavivirus in
the family Flaviviridae. WNV is maintained in a mos-
quito-bird-mosquito transmission cycle [1], whereas
humans and horses are considered dead-end hosts.
WNV is transmitted primarily by the bite of infected
mosquitoes, themselves acquiring the virus by feeding
on infected birds.
The West Nile virus has been reported in dead or dying
birds of at least 326 species [2]. The clinical outcome of
infection is variable e.g. chickens and turkeys are resistant
to disease while some species are particularly susceptible,
e.g. crows, Carolina chickadees, tufted titmice, blue jays,
American robins, and eastern bluebirds.
WNV has a wide geographical range that includes por-
tions of Europe, Asia, Africa, Australia (Kunjin virus) and
North, Central and South America [3]. Migratory birds are
thought to be primarily responsible for virus dispersal,
including reintroduction of WNV from endemic areas
into regions that experience sporadic outbreaks [3].
In humans, it was first isolated in the West Nile pro-
vince of Uganda in 1937 from the blood of a woman
suffering from a mild febrile illness [4]. Until the mid
1990’s, West Nile (WN) disease was considered as a
minor risk for humans and horses because it only
appeared sporadically. The first cases of West Nile virus
in its lethal encephalitic form were reported in Algeria
in 1994. Since the first large outbreak in Romania in
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1996, which was characterized by a high number of neu-
roinvasive cases, and the huge epidemics and equine
epizootics into North America that followed West Nile
virus introduction in New York city in 1999 [5], WN
associated disease has become a major public health and
veterinary concern.
2. West Nile virus
The structure of WNV particles have been elucidated by
Mukhopadhay et al. [6]. Electron microscopy and image
reconstruction techniques established that WNV is a
small spherical icosahedral virus with a 50 nm diameter
and a lipid envelope surrounding an icosahedral nucleo-
capsid consisting of capsid proteins that are associated
with the RNA genome (Figure 1a). The sequence of the
WNV genome and the function of the different viral
proteins in the viral lifecycle as well as immune evasion
have been described in detail elsewhere (Figure 1b)
(reviewed by Ulbert et al. [7]).
During viral entry (Figure 2), the E protein interacts
with one or more cell surface receptor(s). It is not com-
pletely clear which cellular receptors are involved in
WNV binding, however DC-SIGN, alphaVbeta3 integrin
[8] and laminin-binding protein [9] have been reported
as potential receptors. After binding to the cell, the
virus is taken up via clathrin-mediated endocytosis [10]
and in the acidified endosome the E protein undergoes
conformational changes resulting in fusion between the
viral and cellular membranes [11]. After the fusion
event the positive-stranded RNA genome is released
into the cytoplasm of the cell. The viral RNA is trans-
lated into a single polyprotein [12], which is proteolyti-
cally processed to yield three structural proteins (the
envelope protein E; the membrane precursor protein
prM; and the capsid protein C) and seven non-structural
(NS) proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and
NS5). Whereas the cleavages at the junctions C-prM,
prM-E, E-NS1, NS4A-NS4B [13], and likely also NS1-
NS2A [14], are performed by the host signal peptidase
located within the lumen of the ER, the remaining pep-
tide bonds are cleaved by the virus encoded NS3
protease. Flaviviruses replication requires the viral pro-
tein NS5, which is an RNA-dependent RNA polymerase
[15,16]. An “antisense” negative strand RNA is produced
by this enzyme, which then serves as a template for the
synthesis of many new copies of the infectious positive
strand RNA genome.
WNV assembles on virus-induced membranes derived
from the endoplasmic reticulum and buds into the
lumen as immature virions on which E and prM pro-
teins form 60 heterotrimeric spikes. Transit of the
immature virion through the mildly acidic compart-
ments of the trans-Golgi network triggers a rearrange-
ment of E proteins on the immature virion; the lower
pH induces a structural transition such that E proteins
lie flat as antiparallel dimers on the surface of the virion
[17]. Under acidic conditions, prM remains associated
with the virion and protrudes from the surface of an
otherwise smooth virus particle. This pH-dependent
conformational change increases the susceptibility of
prM for a furin-like serine protease. Cleavage and
release of prM completes the virion maturation process,
and is a required step in the virus lifecycle.
Flavivirus nonstructural (NS) proteins modulate the
host antiviral response. This was recently reviewed by
Diamond et al. [18]. Flavivirus NS1 is a versatile non-
structural glycoprotein, with intracellular NS1 function-
ing as an essential cofactor for viral replication [19] and
antagonist of TLR signaling [20], whereas NS1 at the
cell surface and secreted NS1 antagonize complement
activation [21,22]. NS2A is involved in the biogenesis of
virus-induced membranes, which have a vital role in
virus assembly [23]. NS2A also inhibits interferon-b pro-
moter activation [24]. The flavivirus non-structural pro-
tein NS4B and NS5 block activation of the JAK-STAT1
signaling pathway [25], which limits production of anti-
viral interferon stimulated genes in infected cells.
3. Epidemiology
Birds are the primary vertebrate hosts of WNV and in
endemic regions, the virus is maintained in an enzootic
cycle between Culex mosquitoes and birds [1]. Mosquito
Figure 1 The structure (a) and 11 kb long RNA genome (b) of West Nile virus.
De Filette et al. Veterinary Research 2012, 43:16
http://www.veterinaryresearch.org/content/43/1/16
Page 2 of 15
species from other genera are also susceptible to infec-
tion. There is now indirect evidence that WNV is trans-
ported by migratory birds to the temperate areas of
Europe during spring migration [26-28]. Mammals are
less important than birds in maintaining transmission
cycles of the virus as viremia is too low in most of the
mammal species to reinfect mosquitoes. Humans are
regarded as dead-end hosts because the concentration of
virus within the blood is insufficient to infect a feeding
naïve mosquito [29]. However, in humans, the virus can
spread between individuals by blood transfusion and
organ transplantation [30]. Few reports describe the
possible transmission from a mother to her newborn via
the intrauterine [31] route or via breast-feeding [32].
West Nile virus was first isolated in Uganda in 1937
from the blood of a febrile woman [4]. It is now recog-
nized as the most widespread of the flaviviruses, with
geographic distribution in the United States of America,
Australia, Africa and Eurasia. The largest outbreak of
WNV in Europe to date was in Romania in 1996 when
800 clinical cases of neuroinvasive disease were reported
and in 393 cases the presence of WNV was confirmed
[33]. A total of 17 deaths were reported during this out-
break. Between 1997 and 2010 in Europe, WNV infec-
tions have been observed sporadically in Portugal, Spain,
France, Czech Republic, Hungary and Italy and during a
severe outbreak in Russia in 1999 (318 cases) [34].
However in 2010 the epidemiological situation changed
with the second largest outbreak of the disease in the
EU occurring in Greece [35]. During this outbreak 262
cases were confirmed with 197 patients suffering from
West Nile neuroinvasive disease and 33 reported fatal-
ities. In the same year 480 cases of West Nile infections
were detected in Russia and also some cases were
reported in Romania.
In 1999, WNV was detected for the first time in the
Western Hemisphere in New York [36]. During this out-
break 62 human cases of WNV including 7 deaths were
identified in New York. Despite intense mosquito control
measures to minimize human infections, WNV spread
into Canada and the remainder of the lower 48 continen-
tal states. WNV became endemic within 10 years of its
introduction in North America. So far, in the United
States between 1999 and 2010, 30 662 cases were con-
firmed and associated with 1163 deaths [37].
It has been recently proposed that WNV can be
grouped into 7 lineages [38]. Two major genetic lineages
of WNV have been well described based on phylogenetic
analysis [39]. Lineage 1 is widespread and contains iso-
lates from Europe, the USA, the Middle East, India,
Africa and Australia. Lineage 1 is further segregated into
three different clades: 1a, 1b and 1c. WNV-1a is mainly
found in Europe, North America, Middle East and Africa.
This clade can further be divided in six clusters with
Figure 2 West Nile virus life cycle. After binding and uptake, the virion envelope fuses with cellular membranes, followed by uncoating of the
nucleocapsid and release of the RNA genome into the cytoplasm. The viral genome serves as messenger RNA (mRNA) for translation of all viral
proteins and as template during RNA replication. Copies are subsequently packaged within new virus particles which are transported in vesicles to the
cell membrane. Reprinted with permission from PNAS 2002, vol. 99 no. 18 11555-11557. Copyright 2002 National Academy of Sciences, U.S.A.
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distinct evolutionary histories [40]. WNV-1b contains the
Australian Kunjin virus and lineage 1c some Indian iso-
lates. Lineage 2 contains isolates from Southern Africa
and Madagascar. Since 2004 lineage 2 has also been
observed in central [41] and Eastern [42] Europe. In 2010
it caused outbreaks in Romania [43] and Greece [44] and
in 2011 it was detected for the first time in Italy [45]. The
Greek and Italian strains showed the highest homology to
Hungarian and South African strains, differing from the
Russian lineage 2 strains. This means that at least two
lineage 2 strains are circulating in Europe causing severe
disease in humans. In general the lineage 1 viruses are
considered to be more virulent than the lineage 2 viruses.
However, animal experiments have demonstrated that
highly and less neuroinvasive phenotypes exist in both
lineages. Mutations responsible for increasing virulence
in lineage 2 viruses have previously been described in
lineage 1 viruses like the substitution of amino acids at
position 249 for proline in NS3 [46,47]. Also the glycosy-
lation state of the E protein is an important determinant
of pathogenicity [48,49]. Many of the WNV strains
responsible for more severe outbreaks of WN disease are
glycosylated at position 154. The lineage 3 is represented
by a virus strain that was isolated from mosquitoes in the
Czech Republic, designated the Rabensburg virus [50]
and lineage 4 was isolated from a thick from the Cauca-
sus [51]. WNV strains from India belonging to a subclus-
ter of lineage 1 are sometimes classified as lineage 5 [52].
The Sarawak Kunjin virus strain is significantly different
to the other Kunjin viruses, and therefore re-classification
of this virus as lineage 6 has been proposed. Furthermore,
the African virus, Koutango, is closely related to the WN
virus lineages, and could be considered as a seventh
lineage.
4. Pathogenesis
Mosquitoes become infected with WNV after biting a
bird with high-level viremia and may then transmit it to
humans following a blood meal from the host. The
human incubation period of West Nile virus is 2 to 14
days [53]. The majority (~75 to 80%) of humans infected
with WNV usually have no or very mild symptoms.
Approximately 20% of infected patients develop a febrile
illness ("West Nile fever”) with malaise, myalgias, head-
ache and lymphadenopathy [54]. A small number of the
symptomatic cases progress to the neuroinvasive form of
WNV infection [55], which can be characterized by acute
flaccid paralysis, meningitis, encephalitis and ocular man-
ifestations. Overall, only 1 in 150 infections results in the
most severe and potentially lethal form of the disease,
although the relative risk is increased in the elderly or
immunocompromised. Long-term complications (1 year
or more after infection) are common in patients recover-
ing from severe WNV infection. Since no specific therapy
has yet been approved for humans, patients infected with
WNV have limited treatment options. The primary
course of action is supportive. Small numbers of patients
have received antibody therapy against WNV infection
[56] or off-label treatment with IFN-a [57].
In mammals, the initial replication of WNV after mos-
quito inoculation is believed to occur in Langerhans den-
dritic cells. These infected cells migrate to draining
lymph nodes resulting in a primary viremia [58] and a
subsequent infection of peripheral tissues such as the
spleen and kidney. Viremia ensues and after spread to
the visceral organs, WNV may cross the blood-brain bar-
rier (BBB) and enter the central nervous system (CNS).
The mechanism by which WNV cross the BBB remains
largely unknown, although tumor necrosis factor alpha
(TNF-a)-mediated changes in endothelial cell permeabil-
ity have been proposed to facilitate CNS entry [59].
Other models have been proposed like infection of olfac-
tory neurons and spread to the olfactory bulb [60], direct
axonal retrograde transport from infected peripheral neu-
rons [61] or transport of the virus by infected immune
cells trafficking to the CNS [62]. Neuronal infection is
associated with degeneration, a loss of cell architecture,
and cell death. Later in the course of infection, a mono-
nuclear cell infiltrate appears diffusely throughout
infected regions, although it is not clear whether these
inflammatory cells eradicate infection or contribute to
pathogenesis by destroying infected neurons and releas-
ing pro-inflammatory cytokines [63].
The protective immune response to WNV requires
both innate and adaptive immunity. IFN-a and IFN-b
are produced during the earliest stages of WNV infec-
tion after host cell recognition of viral RNA. Mice with
a defect in type I IFN signaling are much more sensitive
to WNV infection than their wild-type counterparts
[64]. The complement also is required for protection
from lethal WNV infection in mice. WNV activates
complement in vivo, and mice lacking the central com-
plement protein C3 showed enhanced lethality after
WNV infection [65]. Macrophage uptake of WNV can
control infection through direct viral clearance,
enhanced antigen presentation, and cytokine and che-
mokine secretion [66]. gδ T cells also directly limit
WNV infection in early immune responses [67]. As they
lack classical MHC restriction, they can react with viral
antigens in the absence of conventional antigen proces-
sing [68]. Furthermore, the importance of adaptive
immunity has also been demonstrated as passive transfer
of immune monoclonal and polyclonal antibodies pro-
tected mice from lethal WNV infection [69]. IgM is cri-
tically important for the control of early WNV infection
and is detectable approximately 4 to 7 days after infec-
tion [70]. After four to five days of illness, IgG antibo-
dies are measurable in patients presumably conferring
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long-term protection against WNV re-infection [71].
Cellular immune responses also control WNV infec-
tions. Cytolytic T cells clear WNV infection by lysing
infected cells directly through the delivery of perforin
and granzymes A and B [68,72]. CD8+ deficient mice
develop persistent WNV infections in the brain and
humans with impaired T cell function are at increased
risk of neuroinvasive WNV infection and poor outcome
[73].
5. Diagnosis
A review of the developments in WNV diagnosis was
published in 2007 by Dauphin et al. [74]. The current
paper focuses more on the new trends in diagnosis
since 2007.
5.1. Nucleic acid based tests for WNV
Because the virus is present at very low levels in human
blood and tissues, an in vitro amplification of the
genetic material is used to enhance the detection rate of
WNV infections. Several investigators have reported
real-time PCR-based detection systems for rapid detec-
tion of WNV infection in clinical samples (Table 1).
These real-time PCR systems rely upon the detection
and quantification of a fluorescent reporter. Single-tube,
real-time RT-PCR shows many advantages over end-
point RT-PCR because it is more rapid, often more sen-
sitive, more specific, and minimizes contamination. In
addition, real-time RT-PCR is easily standardized and
enable nucleic acid quantification. In the simplest and
least expensive system the reporter is the double-strand
DNA-specific dye SYBR Green. A disadvantage is that
SYBR Green will bind to any double-stranded DNA in
the reaction, including non-specific PCR products and
primer-dimers. Papin et al. developed a SYBR Green
based assay [75] that could detect 100% of the different
WNV target region variants in their study, whereas a
TaqMan assay failed to detect 47% of possible single
nucleotide variations in the probe-binding site. Johnson
et al. designed a pan-flavivirus RT-PCR utilizing degen-
erate primers targeting the NS5 gene to allow the detec-
tion of a range of flaviviruses including WNV. This
SYBR Green based RT-PCR was able to detect WNV
however the sensitivity was much lower compared to
WNV-specific TaqMan RT-PCR assays [76]. SYBR
Green has been shown to inhibit the PCR reaction to
some extent and melt curve analysis is complicated by
dye redistribution during melting. Eischeid analyzed the
behavior of other DNA dyes in real-time PCR and
found that EvaGreen and SYTO dyes 13, 16, 80 and 82
outperformed SYBR Green in real-time PCR [77].
The two most popular alternatives to SYBR Green are
TaqMan and molecular beacons, both of which use
hybridization probes and rely on fluorescence resonance
energy transfer (FRET) for quantification. A TaqMan
qRT-PCR for rapid detection of WNV in human clinical
specimens was first developed by Lanciotti et al. [78].
Compared to the traditional RT-PCR assay, this TaqMan
RT-PCR was more sensitive and could detect less than 1
PFU of virus whereas the traditional RT-PCR had a
detection limit of 1 PFU of virus [78]. Chao et al. devel-
oped a multiplex TaqMan RT-PCR for the simultaneous
identification of four different flaviviruses [80], including
YFV, JEV, WNV and SLEV with a detection limit of
respectively 3.5, 2, 10 and 10 PFU/mL. Dyer et al. also
developed a multiplexed TaqMan assay for the detection
of SLE, WNV, Dengue and TBE species [88]. Naze et al.
developed a multiplex real-time RT-PCR assay for the
simultaneous detection and quantification of dengue
virus (DENV) and Chikungunya virus (CHIKV) from
plasma samples [81]. In parallel, a real-time RT-PCR
assay was developed for the detection and quantification
of WNV using the same blood extract and identical
amplification conditions as for DENV and CHIKV [81].
Jiménez-Clavero et al. developed an improved TaqMan
real-time RT-PCR by introducing a minor groove binder
(MGB), a 3’-labeling group that in addition to acting as a
quencher also increases the binding affinity between the
probe and its target sequence [79]. Two different probes
were used and all samples were analyzed in parallel with
the TaqMan RT-PCR described by Lanciotti et al. Both
methods performed comparably in terms of sensitivity
and were able to detect all clade 1a isolates, however
Kunjin and lineage 2 isolates were only detected by the
new TaqMan-MGB real-time PCR.
Molecular beacons, like TaqMan probes, also contain
fluorescent and quenching dyes but FRET only occurs
when the quenching dye is directly adjacent to the fluor-
escent dye. Lee et al. developed a combined RT-PCR,
using a FAM-labeled molecular beacon probe for WNV
detection and a VIC-labeled TaqMan probe for internal
Table 1 Overview of nucleic acid based assays for WNV
detection.
Technique used Reference
SYBR Green RT-PCR [75,76]
TaqMan RT-PCR [78]
TaqMan-MGB RT-PCR [79]
Multiplex RT-PCR [80,81]
Molecular beacon RT-PCR [82]
RT-PCR/ESI-MS [83]
RT-PCR/LDR [84]
RT-PCR/FRET [85]
RT-LAMP [86]
NASBA [87]
Digital PCR Invitrogen
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control detection [82]. The assay was highly specific for
WNV and demonstrated no reactivity with 15 other
viruses.
Grant-Klein et al. combined RT-PCR with electrospray
ionization mass spectrometry (ESI-MS) to detect tick- and
mosquito-born flaviviruses on the Ibis T5000 platform
[83]. The Ibis T5000 analyses DNA and determines the
base composition (AxGxTxCx) of PCR amplicons by
using ESI-MS. For the RT-PCR assay they developed eight
primer pairs able to detect a broad range of flaviviruses.
WNV was correctly detected by RT-PCR/ESI-MS in
blood, serum and urine spiked with WNV demonstrating
that these clinical matrices did not inhibit the detection of
this virus. Using WNV, the sensitivity of the assay was
determined to be approximately 2 PFU/mL.
Rondini et al. developed a sensitive assay for the detec-
tion of both lineages of WNV by coupling multiplex RT-
PCR and ligase detection reaction (LDR) [84]. Multiple
PCR primers amplify three distinct regions of the WNV
cDNA. Each PCR primer contains between one and three
degenerate positions to accommodate minor sequence
variation at the primer binding sites. Within each PCR
amplicon, LDR primer pairs are designed to identify SNPs
(Figure 3). Ligation of the appropriate LDR primers results
in fluorescently labeled products of different lengths that
are then separated using capillary electrophoresis. The
broad strain coverage was confirmed by testing 34 WNV
isolates belonging to lineages 1 and 2. The detection limit
was very low reaching 0.005 and 0.017 PFU for respec-
tively the one-step or two-step procedure. Detection of
LDR products could also be achieved by hybridization to a
universal DNA microarray.
PCR based diagnostic assay requires specialized equip-
ment and well-trained personnel which is difficult to
obtain in developing countries. A relatively inexpensive
assay for WNV is the loop-mediated isothermal amplifica-
tion (LAMP) assay described by Parida et al. [86]. The
LAMP assay is based on the principle of autocycling
strand displacement DNA synthesis performed by Bst
(Bacillus stearothermophilus) DNA polymerase and a set
of two inner primers and two outer primers. The advan-
tage of LAMP is that the amplification reaction can be
performed under isothermal conditions between 63°C and
65°C, thereby obviating the need for a thermal cycler [89].
The RT-LAMP assay of Parida et al. [86] demonstrated a
high degree of specificity for WNV and was more sensitive
than the traditional RT-PCR detecting 0.1 PFU of WNV.
Another technology that works at isothermal condi-
tions is the nucleic acid sequence-based amplification
(NASBA) assay. Lanciotti et al. developed two NASBA
assays each with a different detection format, i.e. electro-
chemiluminescence or 6-carboxyfluorescein-labeled
virus-specific molecular beacon probes, for the detection
of WNV and Saint Louis encephalitis (SLE) [87]. With
these newly developed NASBA assays a diagnosis can be
made within a hour and their sensitivity is similar or
even greater than the sensitivity of their previously devel-
oped TaqMan assay.
A major disadvantage of all real-time PCR techniques is
that new emerging WNV strains may acquire mutations
in the PCR-primer binding sites, which render them unde-
tectable to currently existing assays. In addition, new
WNV isolates belonging to WNV lineage 2 may pose a
problem. Indeed, data from an external quality assessment
of the molecular diagnostic of West Nile virus showed
that some of the participating laboratories could not detect
lineage 2 viruses by their PCR assays [90]. To avoid that
lineage 2 viruses are missed by the assay, Linke et al.
developed a real-time PCR targeting a conserved region of
lineage 1 and 2 WNV [91]. Eiden et al. developed two
real-time quantitative RT-PCRs for the detection of
lineages 1 and 2 WNV strains. The primers and probe
were located either in the 5’-untranslated region or in
NS2A. Both assays allowed detection of both lineages with
high sensitivity [92]. Several groups started to combine
detection and genotyping of WNV by real-time PCR.
Zaayman et al. [85] performed genotyping of WNV strains
Figure 3 Schematic representation of the ligase detection
reaction. PCR products are denatured and common (black) and
discriminating primers (blue and red) annealed. DNA ligase only
ligates those duplexes which contain exact matches and
thermocycling with DNA ligase amplifies the ligated products.
De Filette et al. Veterinary Research 2012, 43:16
http://www.veterinaryresearch.org/content/43/1/16
Page 6 of 15
by means of dissociation-curve analysis using the fluores-
cence resonance energy transfer probe technology whereas
Papin et al. used a genome-wide, multiple primer-based
real-time quantitative PCR assay [93]. Considerable efforts
have been put into the development of a third generation
of PCR, namely digital PCR (dPCR). It involves partition-
ing of a sample into thousands of nanoliter sized droplets
by means of an emulsion droplet generator [94]. Subse-
quently, fluorescent labeled probes are added to the dro-
plets and PCR is performed on a standard thermal cycler.
After the PCR the droplets are analyzed by passing them
in a single file in front of fluorescence detectors. Subse-
quently, the outcome of the reaction is determined using a
rigorous statistical analysis. In a multiplex PCR, the reac-
tion mixture contains varying concentrations of the differ-
ent fluorogenic probes of the same color. It is then
possible to identify the different probes on the basis of
fluorescence intensity. Life Technologies have successfully
applied their dPCR technology for the detection of WNV.
5.2. Serologic diagnosis of WNV infections
Following exposure to WNV, both IgM and IgG antibo-
dies are produced. In most cases, IgM antibodies can be
detected within 4 to 7 days after the initial exposure and
may persist more than one year [95]. In comparison,
anti-WNV IgG are reliably detected ~ 8 days after the
onset of symptoms and they have a limited use in the
initial diagnosis of WNV infection [71]. Flavivirus-
infected sera show cross-reactions in serodiagnosis with
heterologous flavivirus infections. Therefore, the plaque
reduction neutralization test (PRNT) is still used as the
reference assay for specific diagnosis of WNV infection.
However, PRNT is a laborious test and must be carried
out in a biosafety level 3 (BSL-3) facility as viable WNV
viruses are used in this assay. For high-throughput
screening, different ELISA methods (e.g. indirect IgG,
IgM antibody-capture and blocking ELISA) have been
developed over the last years [74]. ELISAs have the
advantage of being rapid, reproducible and less expensive
than other methods.
The WNV blocking ELISA measures the ability of anti-
bodies present in sera to block the binding of a monoclo-
nal antibody (mAb) to the NS1 protein [96-98], the E-
protein [96] or WNV-specific antigens present in cell
extracts of WNV infected cells [99]. The advantage of the
method is that it is species independent as demonstrated
by Blivitch et al. [96,99-101]. Their blocking ELISA based
on the E-protein reliably detected flavivirus antibodies in
several species of domestic mammals including horses,
cows, pigs and cats [100]. Sotelo et al. developed a block-
ing ELISA with a monoclonal antibody recognizing
domain III of the E glycoprotein [102]. After experimen-
tal infection of partridges this blocking-ELISA detected
WNV-specific antibodies as early as 3 days post-infection
whereas neutralizing antibodies were detected by PRNT
at day 10. The diagnostic sensitivity was 100% compared
to PRNT but the specificity was only 79.5%. Kitai et al.
established an epitope-blocking ELISA based on NS1
that differentiated WNV from JEV infections in horse
sera [98]. Since several vaccines under development are
based on the prM and E proteins, NS1 based ELISAs will
still be able to discriminate between vaccinated and natu-
rally infected animals. While comparing different assays,
they observed that neutralizing antibodies were detect-
able on day 7 by PRNT, and anti-WNV antibodies were
observed from day 10 by conventional ELISA and day 12
in their blocking ELISA.
Indirect IgG and IgM antibody-capture ELISA (MAC)
are used primarily for serological detection of WNV in
acute or convalescent serum or CSF samples. However,
there are limitations to these tests such as the lack of cer-
tain anti-species secondary antibody conjugates and cross-
reactivity with other flaviviruses. Alonso-Padilla et al.
described an indirect ELISA for detection of anti-WNV
IgG antibodies based on recombinant insect-cell derived
soluble WNV-E protein [103]. Comparison of this ELISA
based on recombinant E protein with the ELISA using
inactivated whole virus as antigen showed an equivalence
in sera reactivity, with excellent specificity and sensitivity
when compared with the “gold-standard” PRNT technique.
In an attempt to differentiate between St. Louis ence-
phalitis virus (SLEV) and WNV, Chang et al. performed
extensive mutagenesis within the cross-reactive epitopes
of the E proteins of the two flaviviruses. Subsequently,
each mutant E protein was presented on the surface of
virus-like particles (VLP) to evaluate their diagnostic
potential. The assay was validated using human serum
samples from patients infected with SLEV, WNV or
other flaviviruses. It was found that in the MAC-ELISA
higher specificity was obtained using the VLP containing
the mutant antigens [104].
To further improve the specificity of the WNV ELISAs,
fragments of WNV proteins have also been used to dif-
ferentiate between different flaviviruses. The DIII of the
E protein is an immunoglobulin-like domain protruding
from the otherwise smooth particle surface. Studies on
the DIII of the E protein from JEV, DENV and WNV
showed slight differences in their structures, particularly
in areas that constitute virus neutralizing epitopes [105].
This observation led different groups to study the diag-
nostic potential of domain III of the E protein. Beasley et
al. demonstrated that an ELISA with WNV-DIII pro-
duced in bacteria could differentiate clearly between anti-
body responses to WNV and those produced by other
related flaviviruses, such as SLEV, JEV and Murray Valley
encephalitis virus (MVEV) [106].
Other serological tests have been explored for use in
diagnosis of WNV infections. Kitai et al. developed a
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complement-dependent cytotoxicity (CDC) assay (Figure 4)
to measure antibodies to the West Nile virus NS1 protein
in horses [107]. The antigen used for the assay was
obtained from a stably transfected cell line that constitu-
tively expressed the NS1 protein of the WNV Eg101 strain.
After incubation of the cells with heat-inactivated test
serum, commercial rabbit complement is added and
release of lactose dehydrogenase from cells was measured.
A comparison between a conventional ELISA, the blocking
ELISA, and a virus neutralization test (VNT) revealed that
this system detected anti-NS1 antibodies at similar time
points as the conventional ELISA, but later as the VNT
and earlier as the blocking ELISA.
Microsphere-based immunoassays (MIAs) are becom-
ing increasingly popular for the diagnosis of many dis-
eases. This technology is based on the covalent bonding
of antigen to microspheres. The detecting device is a
simplified flow cytometer and the procedure can be
completed in a few hours. Balasuriya et al. developed
four MIAs using recombinant WNV E, NS1, NS3 or
NS5 proteins for the detection of equine IgG antibodies
in sera of vaccinated or naturally infected horses [108].
The NS-based MIAs were less sensitive than both
PRNT and E-MIA. However, the NS1-MIA was able to
distinguish between horses vaccinated with the canary-
pox virus vaccine and horses that were naturally
infected. Johnson et al. produced a human IgM specific
WNV/SLE MIA using recombinant WNV prM and E
and SLEV antigen extracted from mice brains as detect-
ing antigens [109].
A surface enhanced Raman scattering (SERS) immu-
noassay for antibody detection in serum was developed
by Neng et al. [110]. This assay utilizes gold nanoparti-
cles coated with the E protein of WNV as the SERS-
active substrate and protein A/G conjugated with the
Raman tag malachite green (MG) as a bi-functional
Raman tag/antibody binding reporter. The assay was
validated by incubation of the E protein-coated gold
nanoparticles with immune serum from rabbits. Subse-
quent laser interrogation of the sandwiched immuno-
complex revealed a SERS signaling response diagnostic
for MG. Since protein A/G can interact with a range of
mammalian antibody subclasses, this SERS immunoassay
can be used for different mammalian species (but not
avian due to low binding affinity for protein A/G) with-
out the requirement of species specific secondary anti-
body conjugates.
5.3. WNV antigen detection
The VecTest® is an antigen panel assay designed by
Medical Analysis Systems to detect WNV, SLE and East-
ern Equine Encephalitis (EEE). It uses a detection dip-
stick coated with specific antibodies. Although it is less
sensitive than the plaque assay in Vero cells or RT-PCR
[111], it has the advantage that it gives a result in less
than 20 minutes and it does not require sophisticated
equipment.
Two groups developed sensitive antigen capture ELISAs
(ACE) for the detection of secreted NS1. MacDonald et al.
produced two ACEs for the detection of NS1 in experi-
mentally infected hamsters [112]. In their first ACE a poly-
clonal antiserum was used as detecting antibody, and in
their second ACE they used the same monoclonal anti-
body for capturing and detecting the NS1 antigen. The
first ACE was more specific for recombinant forms of
NS1, while the latter detected native NS1 at high sensitiv-
ity. The detection limit was less than 1 ng/mL. Chung et
al. developed a similar ACE using two different monoclo-
nals [113]. Their ACE detected as little as 0.5 ng/mL of
soluble NS1 and showed no cross-reactivity with yellow
fever, Dengue and SLE virus NS1.
A membrane-based electrochemical nanobiosensor
that recognizes viral particles or virus E protein was fab-
ricated by Nguyen et al. by putting a nanoporous alu-
mina membrane over a sensing electrode [114]. IgM
raised against domain III of protein E was used as the
specific biorecognition probe for WNV particles. This
assay was highly sensitive toward whole WNV particles
with a detection limit of 2 viral particles per 100 mL,
which is comparable to PCR techniques. This might be
useful for the detection of virus early during infection of
the host, i.e. before the onset of antibody production.
6. Vaccination
A review of the trends in vaccine development was pub-
lished in 2007 by Dauphin et al. [74]. The current paper
focuses more on the evolution in vaccine development
since 2007.
6.1. Licensed West Nile virus vaccines for animals
Although no human vaccine is available to date, there
are currently three WNV vaccines licensed for horses
(Table 2). The first licensed vaccine was developed by
Fort Dodge Animal Health, which is now subsidiary of
Pfizer. It contains a formalin-inactivated, whole West
Nile virus. This vaccine is currently commercialized in
the USA under the trade name West Nile-Innovator®
Figure 4 CDC assay as developed by Kitai. See text above for
further details.
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and is quite effective. Indeed, 12 months after two doses
of West Nile-Innovator® 94% of the animals were pro-
tected against viremia after challenge. In a safety trial of
the vaccine, less than 5% of the horses showed adverse
responses to vaccination [115]. Another killed virus vac-
cine (Vetera® WNV vaccine) developed by Boehringer
Ingelheim Vetmedica was also licensed by the United
States Department of Agriculture (USDA). A third com-
mercialized WNV vaccine in the United States for
horses is Recombitek® Equine West Nile Virus Vaccine
(Merial, now Sanofi Aventis), which is a chimeric
recombinant canarypoxvirus vaccine [116]. This vaccine
expresses the prM and E genes derived from a 1999
New York isolate of West Nile virus (WNV). All of the
vaccinated horses developed neutralizing antibodies
against WNV and showed significantly fewer clinical
signs of WNV disease upon challenge [117]. Also an
inactivated form of this chimeric vaccine has been
licensed by the USDA. In 2005, a WNV DNA plasmid-
based vaccine was licensed in the United States by Fort
Dodge Animal Health/Pfizer under the trade name of
West Nile-Innovator® DNA. The vaccine contains an
unformulated plasmid DNA encoding the prM and E
protein of WNV and MetaStim™ as adjuvant. The vac-
cine is administered intramuscularly and a second dose
is given two to four weeks after the first. This vaccine
has recently been discontinued by Pfizer. A Flavivirus
chimera vaccine for horses (PreveNile, Intervet) contain-
ing West Nile virus pre-membrane (prM) and envelope
(E) genes (from the NY99 strain) in a backbone of yel-
low fever (YF17D vaccine virus), was granted a full
license by USDA in 2006. However, in 2010 it was
recalled from the market after the observation of
adverse effects like acute anaphylaxis, colics, respiratory
distress and even death in horses.
6.2. WNV vaccines under development
A recombinant influenza virus expressing domain III of
the WNV E protein has been evaluated as a WNV vac-
cine candidate in a mouse model [121]. The WNV DIII
was cloned in the N-terminal region of the influenza
virus neuraminidase destroying the functional activity of
the influenza protein. Subcutaneous immunization of
mice with the vaccine, FLU-NA-DIII, resulted in higher
virus-neutralizing and WNV-specific IgG ELISA titers
than intranasal administration. In addition, cellular DIII-
specific responses as determined by IFN-g ELISPOT
assay were also stronger in the subcutaneously immu-
nized group. After subcutaneous challenge with WNV,
higher morbidity as assessed by loss of body weight was
Table 2 Overview of the different commercialized and candidate West Nile vaccines.
Name Viral antigen(s) State of development Reference
West Nile-Innovator
(Pfizer)
RecombiTek (Merial)
Whole virus
WNV prM-E in
canarypox virus
Commercialized for horses
Commercialized for horses
[63]
West Nile-Innovator
DNA
Plasmid DNA prM/E Licensed for horses [23]
PreveNile
(Intervet)
WNV prM-E in yellow fever backbone Commercialized for horses
(recalled in 2010)
Vetera West Nile
vaccine
(Boehringer Ingelheim)
Killed virus Commercialized for horses
ChimeriVax
(Sanofi)
Yellow fever PrM-E substituted by WNV
prM-E
Phase II human clinical trial [5,8]
WN-DEN4 WNV prM-E in dengue-4 backbone Phase II human clinical trial [72]
VRC303
(NIAID/Vical)
Plasmid encoding WNV prM and E Phase I human clinical trial [41]
STF2Δ.EIII S. typhimurium flagellin fused to E domain
III
Evaluated in mice [55]
rWNV-ET Truncated protein E Evaluated in mice and horses [19,42]
SRIP prM-E VLPs Evaluated in mice and horses [12]
RepliVAX WN Single-cycle West Nile virus Evaluated in mice [118], hamsters [119], non-human primates
[120]
Plasmid encoding E domain III fused to P28 Evaluated in mice [22]
DIII-C-AP205 E domain III coupled to bacteriophage
AP205
Evaluated in mice [87]
FLU-NA-DIII E domain III inserted into NA of influenza Evaluated in mice [54]
CAdVax-WNVII C, preM, E and NS1 expressed in adenovirus Evaluated in mice [81]
De Filette et al. Veterinary Research 2012, 43:16
http://www.veterinaryresearch.org/content/43/1/16
Page 9 of 15
observed in the intranasal immunized group. Survival
rates were 100% and 75% in mice immunized with FLU-
NA-DIII via the subcutaneous or intranasal route,
respectively.
Schepp-Berglind et al. created an adenoviral vaccine
vector (CAdVax-WNVII) expressing four WNV pro-
teins, C, prM, E and NS1. Although these proteins origi-
nated from a lineage II virus strain, serum samples
collected after vaccination of mice with CAdVax-WNVII
contained antibodies that neutralized lineage I and II
viruses. In vaccinated mice T cell activity against WNV
antigens was observed in splenocytes after re-stimulation
in vitro with WNV infected target cells [122].
The emergence of pathogenic lineage 2 strains in Eur-
ope raised the question whether the existing WNV vac-
cines, mainly based on lineage 1 strains, can also protect
against the new circulating lineage 2 strains of WNV.
Minke et al. demonstrated that Recombitek® Equine
West Nile, that expresses the prM/E genes of lineage 1
strain in a recombinant canarypox virus, could protect
horses against a contemporary neurovirulent lineage 2
WNV isolate [123]. Finally, Yamshchikov et al. reported
that an attenuated non-epidemic West Nile virus strain
of lineage 2 can be used as an effective vaccine against a
virulent epidemic strain of lineage 1 in mice [124].
Another strategy that has been evaluated is vaccination
with purified viral proteins. Although these vaccines pro-
tect against disease in animal models, multiple injections
and/or strong adjuvants were required to reach accepta-
ble efficacy. Demento et al. [125] formulated recombi-
nant E protein onto poly(lactic-co-glycolic acid) (PLGA)
nanoparticles that contained CpG oligonucleotides at
their surface. Activation of dendritic cells as determined
by the secretion of IL-6 and IL-12 was stronger when the
CpG-modified E protein-loaded nanoparticles were used
compared with E protein adsorbed to Alhydrogel. C3H/
HeN mice immunized with encapsulated E protein in
CpG modified nanoparticles or with E protein adsorbed
to alhydrogel elicited equivalent titers of IgG however,
the isotype profiles were very different. Only CpG-modi-
fied particles loaded with E protein raised high IgG2a
and IgG2b titers. Lymphocytes from mice vaccinated
with encapsulated E protein in CpG modified nanoparti-
cles produced higher levels of IFN-g and IL-2 in vitro
after re-stimulation with E protein compare to lympho-
cytes from Alhydrogel-rWNV-ET immunized mice.
CD8+CD44+ T cells from mice vaccinated with CpG/
rWNV E nanoparticles had a larger KLRG1+CD127-
population, a subset of terminally differentiated effector
cells.
Martina et al. produced domain III protein of the E
protein of WNV (rDIII) and compared it with a b-pro-
piolactone (BPL) inactivated WNV vaccine [126]. Neutra-
lizing antibodies against WNV were detected in all mice.
Interestingly, cross-neutralizing IgG against JEV also
were produced. Mice vaccinated with rDIII and chal-
lenged with either WNV or JEV were protected against
morbidity as determined monitoring the body weight.
However, the survival rates were lower (80% to WNV
and 60% to JEV) compared to mice vaccinated with BPL
inactivated WNV (100% to WNV and 80% to JEV).
McDonald et al. fused bacterial flagellin to the domain III
of the WNV envelope protein (STF2Δ.EIII) providing the
fusion protein the ability to engage the TLR5 receptor.
Mammalian hosts detect the conserved domain on flagel-
lin monomers through TLR5, which triggers proinflam-
matory and adaptive immune responses. Mice injected
either subcutaneously or intraperitoneally with the flagel-
lin-DIII fusion protein produced significant levels of anti-
WNV E IgG as determined by ELISA. In addition, sera
from vaccinated mice had neutralizing antibody titers >
1/40. In a mouse model, > 90% survival was observed in
animals that were immunized with STF2Δ.EIII [127].
Spohn et al. also have used recombinantly expressed
domain III of the WNV E protein as an immunogen.
This group chemically coupled the DIII protein to VLP
derived from bacteriophage AP205. This conjugate vac-
cine DIII-C-AP205 was more immunogenic in mice than
a mixture of corresponding amounts of free DIII and its
carrier AP205. Neutralizing antibodies could be detected
in 75% of the mice after one injection with the DIII-C-
AP205 vaccine while all animals scored positive after
three injections. The latter group was also fully protected
against a lethal challenge with the virus [128].
Finally, a fourth strategy uses DNA vaccination as a
platform for WNV vaccination. Davis et al. were the first
to demonstrate that plasmid DNA encoding the WNV
membrane (M) and envelope (E) proteins injected intra-
muscularly in mice and horses provided protection
against a WNV challenge [129]. DNA vaccination
resulted in both a humoral response as well as a strong
Th1 response. This study paved the way for the licensing
of the first DNA vaccine for animal use, i.e. West Nile-
Innovator® DNA. Later on, other administration routes
and carrier mediated delivery of the WNV DNA vaccines
have been exploited. Zhao et al. showed that inoculation
of plasmid (mixed with colloidal gold) via intravenous
and intradermal injection elicited stronger and more sus-
tained neutralizing immune responses than intramuscu-
lar or intraperitoneal injection [130]. Prow et al. used a
nanopatch with a microneedle array to deliver a West
Nile virus DNA vaccine that was complexed to poly(ethy-
lenimine) [131]. This simple needle-free technique
resulted into an effective vaccine delivery with a cuta-
neous expression of encoded proteins within 24 h [131].
Dunn et al. evaluated DNA vaccines with derivatives of
the WNV E gene (full length, truncated E or DIII region)
conjugated to the P28 region of the complement protein
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C3d. Mice were vaccinated three times either intramus-
cularly or by the gene gun route. The latter resulted in
higher IgG titers against WNV DIII. Gene gun DNA vac-
cination induced primarily a Th2 response (characterized
by IgG1 antibodies) whereas intramuscular administra-
tion resulted more in a Th1 response (characterized by
IgG2 antibodies). Eighty percent of the mice vaccinated
by gene gun with DIII-DNA survived a lethal WNV chal-
lenge with little weight loss, while no mice survived in
the intramuscularly vaccinated group. However, the sur-
vival rates after IM administration increased to 60% by
conjugating P28 to DIII [132]. At the moment, all the
commercially available DNA vaccines against any patho-
gen contain unformulated DNA. Chang et al. developed a
plasmid DNA (pDNA) that after transfection gives rise to
single-round infectious particles (SRIPs) based on WNV.
Flavivirus RNAs that contain large deletions in the capsid
gene cannot produce infectious virions but retain the
ability to replicate their RNA backbone and express prM
and E proteins. After transfection, the plasmid DNA gen-
erates two different mRNAs: one encoding capsid protein
and the other for the prM, the E, non-structural proteins
and a truncated capsid. Only the latter RNA molecule
can replicate and become incorporated in the SRIPs.
Cells transfected with SRIPs will produce subviral parti-
cles that contain the prM and E-proteins but lack virus
genomic material. This plasmid DNA vaccine was deliv-
ered using a gene-gun with DNA-coated gold particles.
Vaccination of mice with plasmid DNA encoding SRIPs
elicited higher overall and neutralizing antibody titers
than after vaccination with a plasmid encoding prM-E
[133]. After intraperitoneal challenge, all mice vaccinated
with SRIPs were protected against morbidity whereas
some mice in the prM-E DNA plasmid group developed
signs of disease although all mice survived infection. The
SRIP vaccine also was able to induce virus-neutralizing
antibodies in horses. A similar strategy was followed by
Mason et al. They produced RepliVAX WN, a live-atte-
nuated virus in which the gene encoding the capsid pro-
tein was deleted from the WNV genome. Vaccination
with RepliVAX WN induced protective immunity in
mice [118], hamsters [119] and non-human primates
[120]. Nelson et al. characterized the nature of the
immune response to RepliVAX in mice [134]. They
found that the number of B cells secreting IgG specific
for NS1 peaked at day 8 and was dose-dependent. Long-
term presence of NS1-specific plasma cells through 8
months was observed. The IgG subclass of the induced
antibodies was predominantly IgG2 while only little IgG1
was produced. Immunized mice mounted a strong CD8+
T cell response against NS4B2488 and E347 that peaked at
day 6. The cytotoxic activity of these cells was confirmed
by analysis of the killing of peptide-pulsed target cells.
The CD8+ T cells produced TNF-a and IFN-g after sti-
mulation with the NS4B2488 peptide. Significant CD4
+ T
cell responses were also detected against peptides
NS31616, E641, E431 and NS32066 that peaked on day 13.
Specific cytolysis of NS32066 pulsed cells by CD4
+ spleno-
cytes was observed by day 6 and peaked on day 8. CD4+
T cells produced predominantly IFN-g and no IL-4 fol-
lowing restimulation with peptide in vitro. Memory CD4
+ and CD8+ T cells were detected 8 months post immu-
nization [134].
6.3. Clinical trials with West Nile virus vaccines in humans
At present, there are no FDA-approved vaccines for
human use but several clinical trials are ongoing. In
2005, Acambis (Sanofi-Pasteur) successfully completed a
Phase I clinical trial with its live-attenuated Chimeri-
Vax-WN. ChimeriVax-West Nile (Acambis, Sanofi-Pas-
teur) utilizes the attenuated YFV vaccine strain (17D) to
build a live chimeric virus that consists of the prM and
E proteins of WNV in the context of the YFV capsid
and non-structural proteins [135]. ChimeriVax-West
Nile is the most advanced vaccine in development. In
the first part of a Phase II trial in healthy adults 18-40
years of age, a single dose of ChimeriVax-West Nile
raised neutralizing antibodies 28 days after vaccination
[135]. The second part of the Phase II trial determined
safety and tolerance in healthy individuals over 41 years
of age. Seroconversion was achieved at day 28 by more
than 96% of the healthy adults in both age groups.
Another chimeric vaccine (WN-DEN4) that uses attenu-
ated dengue virus as a backbone for prM-E genes of
WNV [136] is being evaluated in a Phase II human trial
at the John Hopkins School of Public Health in adults
18-50 years of age. The Vaccine Research Center (VRC)
at the National Institute of Allergy and Infectious Dis-
eases (NIAID) has, in collaboration with Vical, devel-
oped a DNA plasmid-based vaccine. In 2005, the VRC
initiated a successful Phase I clinical trial demonstrating
its safety, tolerability and ability to induce neutralizing
antibodies. Subsequently, a second-generation DNA vac-
cine using an improved vector was evaluated in a Phase
I clinical trial. Naked plasmid DNA was administered
via needle-free intramuscular injection on days 0, 28
and 56 with at least 21 days between injections. The
plasmid in this vaccine is incapable of replicating in ani-
mal cells and does generate infectious virions. The vac-
cine was well tolerated without serious adverse events.
All individuals that completed the 3-dose vaccination
schedule developed neutralizing antibodies [137]. The
majority of the subjects developed a CD4+ response
rather than a CD8+ response as assessed by intracellular
cytokine staining. Vaccine-induced T cell responses
were mainly directed against WNV E protein.
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7. Conclusions
West Nile virus remains a serious threat to the public
health, especially to very young, elderly and immunocom-
promised individuals. There is currently no antiviral
treatment to cure WNV infections and only supportive
care can be administered. Ribavirin [138], interferon-a
[57,139] and WNV-specific immunoglobulin [56,140]
have all been considered as specific treatments for WNV
disease, but no rigorously conducted clinical trials have
been completed. Diagnostic tests have improved consid-
erably and allow a rapid detection of the presence of
WNV. Vaccine development against WNV continues to
progress. Four WNV vaccines are currently available in
the USA for horses. Although several clinical trials in var-
ious phases in humans are ongoing, it will take several
years before any vaccine is available. Given the relatively
low incidence of WNV neuroinvasive disease in healthy
individuals and the focal occurrence of WNV epidemics
thus far, vaccination will likely target the groups at higher
risk for WNV neuroinvasive infection. At the moment,
the best way to prevent West Nile virus infection remains
to avoid mosquito bites.
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